TY - JOUR
T1 - Self-Efficacy and the Impact of Inflammatory Bowel Disease on Patients’ Daily Lives
AU - Sheehan, Jessica L.
AU - Greene-Higgs, La Vana
AU - Swanson, Linnea
AU - Higgins, Peter D.R.
AU - Krein, Sarah L.
AU - Waljee, Akbar K.
AU - Saini, Sameer D.
AU - Berinstein, Jeffrey A.
AU - Mellinger, Jessica L.
AU - Piette, John D.
AU - Resnicow, Ken
AU - Cohen-Mekelburg, Shirley
N1 - Publisher Copyright:
© 2023 The Author(s).
PY - 2023
Y1 - 2023
N2 - INTRODUCTION: Self-efficacy, i.e., the confidence in one’s capacity to perform a behavior, is crucial to the development of inflammatory bowel disease (IBD) self-management skills. We aimed to measure IBD self-efficacy and the relationship between self-efficacy and the patient-reported impact of IBD on daily life. METHODS: We surveyed patients with IBD from a single academic center using the IBD Self-Efficacy Scale (IBD-SES) and patient-reported outcome (PRO) measures. The IBD-SES assesses 4 IBD domains: patients’ confidence in managing stress and emotions, symptoms and disease, medical care, and remission. IBD PROs evaluate daily life impact, coping strategies, emotional impact, and systemic symptoms. We examined the association between IBD-SES domains with the lowest scores and IBD daily life impact. RESULTS: A total of 160 patients completed the survey. Domain scores on the IBD-SES were lowest for managing stress and emotions (mean 6.76, SD 1.86) and symptoms and disease (mean 6.71, SD 2.12) on a 1–10 scale. Controlling for age, sex, IBD type, disease activity, moderate-to-severe disease, depression and anxiety, a higher confidence in managing stress and emotions (b 20.12, 95% confidence interval 20.20 to 20.05, P 5 0.001), and managing symptoms and disease (b 20.28, 95% confidence interval 20.35 to 20.20, P < 0.001) were each associated with lower IBD daily life impact. DISCUSSION: Patients with IBD report low confidence in managing stress and emotion and managing symptoms and disease. Higher self-efficacy in these domains was associated with lower IBD daily life impact. Self-management tools that promote self-efficacy in managing these domains have the potential to reduce IBD’s daily life impact.
AB - INTRODUCTION: Self-efficacy, i.e., the confidence in one’s capacity to perform a behavior, is crucial to the development of inflammatory bowel disease (IBD) self-management skills. We aimed to measure IBD self-efficacy and the relationship between self-efficacy and the patient-reported impact of IBD on daily life. METHODS: We surveyed patients with IBD from a single academic center using the IBD Self-Efficacy Scale (IBD-SES) and patient-reported outcome (PRO) measures. The IBD-SES assesses 4 IBD domains: patients’ confidence in managing stress and emotions, symptoms and disease, medical care, and remission. IBD PROs evaluate daily life impact, coping strategies, emotional impact, and systemic symptoms. We examined the association between IBD-SES domains with the lowest scores and IBD daily life impact. RESULTS: A total of 160 patients completed the survey. Domain scores on the IBD-SES were lowest for managing stress and emotions (mean 6.76, SD 1.86) and symptoms and disease (mean 6.71, SD 2.12) on a 1–10 scale. Controlling for age, sex, IBD type, disease activity, moderate-to-severe disease, depression and anxiety, a higher confidence in managing stress and emotions (b 20.12, 95% confidence interval 20.20 to 20.05, P 5 0.001), and managing symptoms and disease (b 20.28, 95% confidence interval 20.35 to 20.20, P < 0.001) were each associated with lower IBD daily life impact. DISCUSSION: Patients with IBD report low confidence in managing stress and emotion and managing symptoms and disease. Higher self-efficacy in these domains was associated with lower IBD daily life impact. Self-management tools that promote self-efficacy in managing these domains have the potential to reduce IBD’s daily life impact.
KW - Crohn’s disease
KW - behavioral intervention
KW - self-management
KW - ulcerative colitis
UR - https://www.scopus.com/pages/publications/85150382370
UR - https://www.scopus.com/pages/publications/85150382370#tab=citedBy
U2 - 10.14309/ctg.0000000000000577
DO - 10.14309/ctg.0000000000000577
M3 - Article
C2 - 36881812
AN - SCOPUS:85150382370
SN - 2155-384X
VL - 14
JO - Clinical and translational gastroenterology
JF - Clinical and translational gastroenterology
IS - 6
M1 - e00577
ER -